Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tedizolid Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.79 |
| ▸ | MAOB | P27338 | 2/20 | 0.79 |
| ▸ | CALML3 | P27482 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tedizolid Phosphate SCHEMBL1990278 | 1.00 | MAOA (0.79) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid Phosphate SCHEMBL29377855 | 1.00 | MAOA (0.79) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid Phosphate SCHEMBL29766931 | 1.00 | MAOA (0.79) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL20216092 | 0.96 | MAOA (0.81) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL13144441 | 0.96 | MAOA (0.81) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL1990275 | 0.95 | MAOA (0.82) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL13144426 | 0.95 | MAOA (0.76) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL2189136 | 0.95 | MAOA (0.76) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL12997802 | 0.95 | MAOA (0.78) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL12997803 | 0.95 | MAOA (0.78) | MAOAMAOBCALML3CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442829-B2 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | claimed |
| EP-2393808-B1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | claimed |
| US-10189870-B2 | Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof | HANGZHOU PUSHAI PHARMAEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-01-29 | — | — | US | claimed |
| US-10065947-B1 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | MERCK SHARP & DOHME CORP. (US) | 2018-09-04 | — | — | US | claimed |
| US-20180244704-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | MERCK SHARP & DOHME LLC | 2018-08-30 | — | — | US | claimed |
| US-9988406-B2 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | claimed |
| US-20170275315-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | claimed |
| US-9624250-B2 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | claimed |
| US-20160176905-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | MERCK SHARP & DOHME LLC | 2016-06-23 | — | — | US | claimed |
| US-20130310343-A1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN- 5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | TRIUS THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | claimed |
| US-8426389-B2 | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | TRIUS THERAPEUTICS, INC. (US) | 2013-04-23 | — | — | US | claimed |
| EP-2393808-A1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | Trius Therapeutics (US) | 2011-12-14 | — | — | EP | claimed |
| EP-1699784-B1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2011-06-29 | — | — | EP | claimed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | claimed |
| US-20100227839-A1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN- 5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | TRIUS THERAPEUTICS (US) | 2010-09-09 | — | — | US | claimed |
| WO-2010091131-A1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | TRIUS THERAPEUTICS (US) | 2010-08-12 | — | — | WO | claimed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | claimed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | claimed |
| CN-115873036-A | Synthetic method of tedizolid phosphate | 中国药科大学 | 2023-03-31 | — | — | CN | disclosed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244704-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | ALPI, PYGL, PYGM | MAOA 2612/4885MAOB 3066/4885CALML3 1240/4885 |
| US-10065947-B1 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | ALPI, PYGL, PYGM | MAOA 2612/4885MAOB 3066/4885CALML3 1240/4885 |
| US-20100227839-A1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN- 5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | ALPI, PYGL, PYGM | MAOA 2392/4885MAOB 2957/4885CALML3 1201/4885 |
| US-10442829-B2 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | ALPI, PYGL, PYGM | MAOA 2612/4885MAOB 3066/4885CALML3 1240/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | MAOA 4398/4885MAOB 4248/4885CALML3 1992/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | MAOA 3819/4885MAOB 3591/4885CALML3 2192/4885 |
| US-20170275315-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | ALPI, PYGL, PYGM | MAOA 2612/4885MAOB 3066/4885CALML3 1240/4885 |
| US-20130310343-A1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN- 5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | ALPI, PYGL, PYGM | MAOA 2482/4885MAOB 2923/4885CALML3 1189/4885 |
| US-10189870-B2 | Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof | OXA1L, PDCD2L, NOD2 | MAOA 822/4885MAOB 915/4885CALML3 2797/4885 |
| US-20160176905-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | ALPI, PYGL, PYGM | MAOA 2612/4885MAOB 3066/4885CALML3 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.